Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
USA - English
Share this article
Share this article
SINGAPORE, June 3, 2021 /PRNewswire/ Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs). Being able to predict an individual s response will help clinicians determine if EGFR-TKIs are a suitable therapeutic option for the patient. The partnership between Vela Diagnostics and NCCS aims to refine the therapeutic management of cancer to improve clinical outcomes.
New research institute and center launched to advance regenerative medicine in Singapore eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
New study launched to more accurately diagnose early hepatocellular carcinoma
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally. In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively.
While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre study led by the National Cancer Centre of Singapore (NCCS) called EarLy DEtection of HCC: miRNA, microbiome and imaGing biomArkers in the evolution of chroNiC livEr Disease in a high-risk prospective cohort (ELEGANCE), addresses thi
E-Mail
IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more
Credit: Image credit: Mole DJ et al. Plos One. 2020;15(12):e0238568
Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.
Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual s risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.